BioCentury
ARTICLE | Company News

Alnylam, Isis Pharmaceuticals, Tekmira drug delivery news

October 1, 2012 7:00 AM UTC

Alnylam said the U.S. District Court for the District of Massachusetts denied a motion from Tekmira to dismiss for lack of standing five out of six claims in a patent infringement suit filed by Alnylam and Isis related to patents covering Alnylam's short interfering RNA and lipid nanoparticle drug delivery technologies. The Court ruled that Alnylam has standing in suing Tekmira for infringement of several patents Tekmira exclusively licensed to Alnylam. In the suit, Alnylam said that by providing lipid nanoparticle-formulated siRNA molecules to Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) under a 2010 deal, Tekmira infringed U.S. Patent Nos. 7,695,902; 6,858,225; 6,815,432; 6,534,484; 6,586,410; and 6,858,224. The patents are owned by Tekmira and licensed to Alnylam. Tekmira filed the motion to dismiss earlier this year (see BioCentury, May 17, 2010, Jan. 23, 2012 & March 12, 2012). ...